Form 4: LiPella Pharmaceuticals CFO Acquires 50,000 Stock Options
SEC Filing Form 4
Douglas Johnston, CFO of LiPella Pharmaceuticals, reports the acquisition of 50,000 stock options on March 15, 2024.
Summary
- Douglas Johnston, the Chief Financial Officer of LiPella Pharmaceuticals Inc., filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on March 15, 2024.
- Johnston acquired 50,000 stock options with an exercise price of $0.77.
- These options are exercisable from March 15, 2024, and expire on March 15, 2034.
- Following the reported transaction, Johnston directly owns 50,000 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports a transaction.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests.
Stakeholder Impact
- The acquisition of stock options by the CFO could be viewed positively by shareholders as it aligns management's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of earliest transaction: CFO acquired 50,000 stock options. |
| 03/15/2024 | Stock options become exercisable. |
| 03/15/2034 | Expiration date of the stock options. |
| 03/19/2024 | Date of signature on the Form 4 filing. |
Keywords
Form 4, insider trading, stock options, LIPO, LiPella Pharmaceuticals, Douglas Johnston, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.